Maravai LifeSciences Holdings, Inc.
MRVI
$2.45
$0.062.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.73% | -27.00% | -23.92% | -2.49% | 0.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.73% | -27.00% | -23.92% | -2.49% | 0.74% |
| Cost of Revenue | 2.71% | 2.06% | 6.65% | 0.38% | -10.84% |
| Gross Profit | -74.81% | -70.11% | -51.42% | -5.98% | 20.28% |
| SG&A Expenses | -4.88% | -3.23% | 19.97% | 0.57% | 14.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.16% | -0.80% | 12.38% | 0.45% | 1.47% |
| Operating Income | -143.79% | -82.97% | -44,103.28% | -15.54% | -5.09% |
| Income Before Tax | -255.43% | -135.13% | -107.09% | -754.17% | -56.05% |
| Income Tax Expenses | -76.10% | -40.22% | -100.00% | 105.69% | -71.36% |
| Earnings from Continuing Operations | -279.14% | -133.04% | 57.72% | -1,065.11% | -54.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 250.43% | 116.07% | 405.84% | 790.24% | 59.77% |
| Net Income | -304.44% | -147.93% | 75.33% | -1,432.62% | -49.66% |
| EBIT | -143.79% | -82.97% | -44,103.28% | -15.54% | -5.09% |
| EBITDA | -917.71% | -185.15% | -233.25% | -49.31% | 48.06% |
| EPS Basic | -280.72% | -128.70% | 77.00% | -1,327.76% | -45.36% |
| Normalized Basic EPS | 155.41% | 50.00% | -99.93% | 2,275.24% | -13.47% |
| EPS Diluted | -280.72% | -128.70% | 77.00% | -1,300.00% | -45.36% |
| Normalized Diluted EPS | 155.41% | 50.00% | -99.93% | 2,275.24% | -13.47% |
| Average Basic Shares Outstanding | 6.18% | 8.38% | 7.32% | 7.30% | 3.02% |
| Average Diluted Shares Outstanding | 6.18% | 8.38% | 7.32% | 7.30% | 3.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |